# Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care

> **NCT04362085** · PHASE3 · COMPLETED · sponsor: **Unity Health Toronto** · enrollment: 465 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Therapeutic Anticoagulation

## Key facts

- **NCT ID:** NCT04362085
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-11
- **Primary completion:** 2021-05-10
- **Final completion:** 2021-10-14
- **Target enrollment:** 465 (ACTUAL)
- **Last updated:** 2025-01-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04362085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04362085, "Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04362085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*